Miderizone (Tolperisone Hydrochloride)

Tolperisone Hydrochloride, the active ingredient in Miderizone, is a centrally acting skeletal muscle relaxant presented as an oral tablet for oral use. It reduces muscle spasm and associated pain in adults with musculoskeletal conditions.

GNH USA supplies Miderizone as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tolperisone Hydrochloride is used to manage conditions involving skeletal muscle hypertonia.

- Muscle spasm: alleviates involuntary muscle contractions and reduces associated pain. - Musculoskeletal pain: improves comfort by relaxing tense muscles that contribute to pain. - Spasticity: decreases muscle tone in disorders such as post‑stroke or multiple sclerosis.

Tolperisone Hydrochloride may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild stomach upset. - Headache: occasional mild headache. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Hypotension: significant drop in blood pressure. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

When prescribing Tolperisone Hydrochloride, clinicians should consider several safety aspects.

- Renal impairment: adjust use if kidney function is reduced. - Hepatic disease: monitor liver function during therapy. - Cardiovascular disorders: use cautiously in patients with low blood pressure. - Concomitant CNS depressants: may enhance sedative effects. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep below 25°C, protect from moisture and light in original packaging.

Tolperisone Hydrochloride can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other muscle relaxants: additive muscle weakness. - Antihypertensive agents: may potentiate blood pressure lowering. - CYP450 inhibitors (e.g., erythromycin): could increase plasma levels.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): enhanced sedation. - Anticholinergic drugs: possible increase in anticholinergic burden. - Diuretics: monitor electrolyte balance.